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INTRODUCTION
Accumulating evidence suggests that adipose tissue is not
only used for energy storage but it also secretes compounds with
important endocrine activity. One of these factors is adiponectin,
a 30-kDa protein primarily synthesized by adipocytes and also
produced by skeletal muscles, endothelial cells and
cardiomyocytes (1). Adiponectin circulates in the bloodstream at
high level in three molecular forms: low molecular weight (LMW)
trimeric form, medium molecular weight (MMW) hexameric
form and high molecular weight (HMW) multimers (2). HMW
adiponectin seems to represent the most biologically active
oligomeric form (3). Adiponectin mediates beneficial effects on
the cardiovascular system by acting directly on the component
cells in the heart and blood vessels (4). It was reported that low
circulating HMW adiponectin levels of circulating HMW
adiponectin are a risk factor for cardiovascular events (5).
Clinical investigations have demonstrated markedly lower
plasma total adiponectin levels in patients with coronary artery
disease (CAD) (6), as well as in patients with heart failure (7). It
was reported that adiponectin is associated with central obesity
and cardiovascular disease (CVD) (8). Animal studies have
indicated that adiponectin is a cardiovascular protective
molecule. In response to artery ligation followed by reperfusion,
adiponectin knockout mice (APN-KO) had a significantly larger
infarct size, greater myocardial cell apoptosis and increased
tumor necrosis factor-α (TNF-α) expression compared with
wild-type controls (9). Although higher adiponectin levels were
detected in damaged cardiomyocytes, additional studies have
also demonstrated that plasma adiponectin levels rapidly
declined after induction of myocardial ischemia-reperfusion
injury, supporting the role of adiponectin in cardiac pathologies
including myocyte hypertrophy and diastolic dysfunction (8).
However, it is still not clear whether adiponectin plays beneficial
or detrimental role in the course of heart failure. Thus, detailed
studies based on the experimental model are required to explain
in details the influence of adiponectin on heart failure. In this
regards, the aim of this study was to investigate the effects of
myocardial infarction-induced heart failure on total and HMW
adiponectin concentrations in plasma, adipose tissue and cardiac
tissue in the rat model of chronic heart failure that mimics
typical systolic chronic heart failure in humans.
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Adiponectin is a protein secreted primarily by adipose tissue. It has been suggested that adiponectin plays a protective
role in the early phase following myocardial infarction. Our primary aim was to investigate the effects of post-myocardial
infarction heart failure well-characterized by left ventricular hemodynamic parameters on the total and high molecular
weight adiponectin concentrations in plasma, fat and cardiac tissue. Eight weeks after myocardial infarction or sham
operation, total and high molecular weight adiponectin concentrations in plasma, fat, and cardiac tissues were assayed in
rats. In addition, hemodynamic parameters and expression of the genes encoding atrial natriuretic peptide and brain
natriuretic peptide in left ventricle were evaluated. Atrial natriuretic peptide and brain natriuretic peptide mRNA levels in
left ventricle tissue were higher in rats with myocardial infarction-induced heart failure compared with the controls.
Similarly, total adiponectin concentration was increased in left ventricle (but not in right ventricle) in rats with post-
myocardial infarction heart failure. In contrast, adiponectin levels in plasma and cardiac adipose tissue in rats with post-
myocardial infarction heart failure were lower than in sham-operated animals. Furthermore, there were no significant
differences in levels of high molecular weight adiponectin in plasma, cardiac tissue or adipose tissue between these two
groups. We conclude that in the rat model of post-myocardial infarction heart failure, adiponectin level is increased in left
ventricle tissue. This is accompanied by decreased adiponectin levels in plasma and cardiac adipose tissue.
K e y  w o r d s : adiponectin, high molecular weight adiponectin, left ventricle, myocardial infarction heart failure, adipose tissue,
coronary artery disease, cardiovascular disease
MATERIALS AND METHODS
Animals and treatments
Twenty-four 10-week-old male Wistar rats (Medical
University of Bialystok, Poland) weighting 260 – 310 g were
used in this study. Animals were housed under controlled
condition of temperature 22°C and lighting (10:14 h). Two
animals were kept in standard cages with free access to water
and standard pelleted food ad libitum.
All animal procedures conformed to the Guide for the Care
and Use of Laboratory Animals published by the US National
Institute of Health (NIH publication No. 85-23, revised 1996)
and were approved by the local Ethics Committee.
Myocardial infarction (MI) was induced in 15 rats, as
described previously (10). Briefly, the rats were anesthetized
with ketamine HCl and xylazine (100 and 5 mg/kg body weight
given IP, respectively) and left thoracotomy was performed. The
heart was externalized and a suture (5 – 0 silk) was looped
around the proximal left coronary artery and tied tightly. The
heart was then internalized, the chest closed and pneumothorax
was reduced. Nine rats forming the sham-operated group were
subjected to the same protocol except that the artery snare was
not tied.
During the following 8 weeks, 7 of the rats with MI died. At
this point, the 8 surviving MI rats and the 9 sham-operated
animals underwent echocardiographic assessment and left
ventricle (LV) catheterization. Subsequently, blood samples
from the inferior vena cava were collected in sterile tubes
containing EDTA (1.6 mg/mL of blood) and aprotinin protease
inhibitor (50 KIU/mL of blood) (BD Diagnostics, Plymouth,
UK). These samples were centrifuged at 4°C and the plasma was
stored in aliquots at –70°C for ELISA. The animals were then
euthanized, the heart was removed and the right ventricle (RV)
was separated from the LV. Cardiac and adipose tissue depots
(subcutaneous, mesenteric, cardiac and epididymal) were
collected, frozen in liquid nitrogen and stored at –70°C for
further protein analysis.
Echocardiography and left heart catheterization
Echocardiography was performed using a MyLab25 (Esaote,
Italy) with 13 MHz linear array transducer. Under light
anesthesia (ketamine HCl and xylazine, respectively 75 mg and
3.5 mg/kg body weight, IP) LV end-diastolic and end-systolic
diameters, as well as wall thickness were determined from the
short-axis view at the midpapillary level. Contractility of 23 wall
segments was graded as 1 (normal) or 0 (abnormal) and the
WMI (wall motion index) was calculated. Normal hearts had a
WMI = 23. Our previous study revealed that WMI is closely
correlated with infarct size and that a WMI = 15 corresponds to
an infarct size of ~40% (11). The LV ejection fraction (LVEF)
was calculated as (LV diastolic area - LV systolic area)/LV
diastolic area, both planimetered from the parasternal long-axis
view.
Under light anesthesia, a micromanometer-tipped catheter
(Millar Instruments, Houston, TX) was inserted through the right
carotid artery into the LV to record LV pressures and the peak
rates of the rise and decline of LV pressure (dP/dtmax and
dP/dtmin).
RNA isolation and quantitative real-time PCR
Heart LV samples from rats with post-MI heart failure (n =
5) and the sham-operated group (n = 6) were homogenized using
a MagNA Lyser Instrument (Roche Diagnostics GmbH,
Mannheim, Germany). Total RNA was then isolated with the
MagNA Pure Compact System (Roche Diagnostics GmbH,
Mannheim, Germany) according to the manufacturer’s
instructions. cDNA was synthesized using a QuantiTect Reverse
Transcription kit (Qiagen GmbH, Hilden, Germany) according
to the manufacturer’s protocol. qRT-PCR amplification of
fragments of the Nppa (natriuretic peptide precursor A; ANP)
and Nppb (natriuretic peptide precursor B; BNP) genes was
performed in a LightCycler 1.5 using LightCycler FastStart
DNA Master SYBR Green I (Roche Diagnostics GmbH,
Mannheim, Germany). Relative expression levels, corrected for
amplification efficiency, were analyzed using REST-MCS©-
version 2 software (12). The amplification of a fragment of the
constitutively expressed Gapdh gene was used as an internal
control for data normalization. Primer sequences and parameters
of qRT-PCR reactions are available upon request.
Measurement of total and high molecular weight adiponectin
concentrations
Frozen adipose and cardiac tissues from rats with post-MI
heart failure (n = 8) and sham-operated animals (n = 9) were
pulverized in liquid nitrogen and homogenized in cold lysis
buffer containing 0.02 M Tris (pH 8.0), 0.137 M NaCl, 10%
glycerol (v/v), 1% Nonidet P-40 (v/v), 0.01 M
ethylenediaminetetraacetic acid (EDTA), 0.1 M NaF, 0.001 M
phenylmethylsulfonyl fluoride (PMSF), 0.25 TIU/mL aprotinin,
and 10 µg/mL leupeptin. Homogenates were incubated for 15
min at 4°C and centrifuged at 15,000g for 15 min at 4°C. The
supernatants were collected and stored at –70°C until the time of
assay.
Total and HMW rat adiponectin levels in plasma, adipose
tissue and myocardium homogenates were determined using kits
for adiponectin ELISA (Mediagnost, Reutlingen, Germany) and
HMW adiponectin ELISA (Shibayagi Co., Ltd., Gunma, Japan),
respectively, in accordance with the manufacturer’s instructions.
The sensitivities of the total adiponectin and HMW adiponectin
assays were less than 0.081 ng/ml and 0.021 ng/ml, respectively.
Intra-assay and inter-assay precisions were 3% and 5% for total
adiponectin assay, and 6% and 5% for HMW adiponectin
assessment.
Protein concentrations in adipose tissue and heart
homogenates were determined using Bradford Reagent (Sigma-
Aldrich, Inc., St. Louis, MO, USA) with bovine serum albumin
as the standard.
Statistical analysis
Data are presented as the mean ± S.D. or median and
interquartile range (min/max). Statistical analyses were
performed using Statistica 10 (StatSoft Inc., Tulsa, OK, USA).
Normal data distribution was verified by the Shapiro-Wilk test,
while homogeneity of variances was confirmed with the
Levene’s test. Student’s t-test was used to assess statistical
significance, whereas the Mann-Whitney U test was performed
when non-parametrical testing was required. Spearman’s rank
correlation coefficients were used to assess the relationship
between adiponectin concentration and various covariates.
Statistical significance was accepted at P < 0.05.
RESULTS
Characteristics of the rat model of post-myocardial infarction
heart failure
There was no significant difference between body mass
between rats with post-MI heart failure (347 ± 16 g) and sham
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operated animals (366 ± 22 g). Eight weeks after the induction
of MI, rat hearts exhibited LV dilation and profound systolic and
diastolic dysfunction (Table 1). Quantitative real-time PCR
(qRT-PCR) determination of the levels of Nppa (ANP) and Nppb
(BNP) mRNAs in the LV showed that the expression of both
genes was significantly higher in rats with post-MI heart failure
than in the sham-operated animals (Fig. 1A and 1B). The
pronounced increase in left ventricular end-diastolic pressure
(LVEDP; Table 1) and increased ANP and BNP genes expression
(Fig. 1A and 1B) supported the diagnosis of advanced heart
failure in this model.
Total and high molecular weight adiponectin levels in the left
and right ventricles in the rat model of post-myocardial
infarction heart failure
Eight weeks after the induction of MI, the level of total
adiponectin had increased in the LV compared to the controls
(Fig. 2). The adiponectin level in the right ventricle (RV) in rats
with post-MI heart failure was similar to the concentration found
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 Sham 
(n = 9) 
MI 
(n = 8) 
WMI 22.2 ± 0.7 12.6 ± 0.9* 
LVSP (mmHg) 124.8 ± 9.2 92.0 ± 11.9* 
LVEDP (mmHg) 5.9 ± 0.6 21.4 ± 2.6* 
dP/dtmax
 
 (mmHg/s) 6212 ± 300 3249 ± 833* 
dP/dtmin
 
 (mmHg/s) 4325 ± 250 2531 ± 616* 
LVDa (mm
2
) 41 ± 2 72 ± 9* 
EF (%) 51 ± 3 20 ± 6* 
 
dP/dtmax and dP/dtmin - peak rate of rise and decline of LV pressure; EF - ejection fraction; LVDa - left ventricular diastolic area; LVEDP
- left ventricular end-diastolic pressure; LVSP - left ventricular systolic pressure; n-number of rats; WMI - wall motion index. Results
are means ± S.D. * P < 0.001 by Mann-Whitney U test between rats with post-MI heart failure vs. sham-operated rats.
Table 1. Hemodynamic parameters in rats with post-myocardial infarction heart failure (MI) and sham-operated rats (Sham) 8 weeks
after surgery.
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Fig. 1. Changes in left ventricle expression of atrial natriuretic
peptide (A) and brain natriuretic peptide (B) mRNAs in rats with
post-myocardial infarction heart failure (MI; n = 5) and sham-
operated rats (n = 6), 8 weeks after surgery. Results are means ±
S.E.M. * P < 0.05, ** P < 0.001.
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Fig. 2. Total adiponectin concentrations in the left and right
ventricle homogenates in rats with post-myocardial infarction
heart failure (MI; n = 8) and sham-operated rats (n = 9), 8 weeks
after surgery. Results are median and interquartile range
(min/max). ** P < 0.005 by the Mann-Whitney U test.
in the sham-operated group (Fig. 2). Post-MI heart failure had no
significant effect on HMW adiponectin levels in either the LV or
the RV (data not shown).
In the rat model of post-MI heart failure there was a positive
correlation between plasma and LV adiponectin levels (r =
0.833, P < 0.01) (Fig. 3A). Furthermore, RV adiponectin
concentrations correlated with left ventricular diastolic area
(LVDa) (r = 0.783, P < 0.02) (Fig. 3B) and left ventricular
systolic area (LVSa) (r = 0.719, P < 0.04) (Fig. 3C) in rats with
post-MI heart failure.
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Fig. 3. Correlations between: total adiponectin concentrations in plasma and left ventricle (A), adiponectin concentration in right
ventricle and left ventricular diastolic area (B) or left ventricular systolic area (C), adiponectin concentration in subcutaneous adipose
tissue and body weight (D), adiponectin plasma levels and left ventricular systolic area (E) in rats with post-myocardial infarction heart
failure (MI; n = 8), 8 weeks after surgery. Spearman’s correlation coefficients and P-values.
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Levels of total and high molecular weight adiponectin
in adipose tissue in the rat model of post-myocardial infarction
heart failure
The total adiponectin concentration in cardiac fat was found
to be markedly reduced in rats with post-MI heart failure
compared with the controls (Fig.4), whereas concentrations of
the HMW form did not differ significantly between these two
groups (data not shown). There was no significant difference
between rats with post-MI heart failure and sham-operated
animals in total adiponectin levels in subcutaneous, mesenteric
and epididymal adipose tissue depots (Fig. 4), or their respective
HMW levels (data not shown).
Adiponectin concentrations in subcutaneous adipose tissue
correlated inversely with body weight (r = –0.738, P < 0.04)
(Fig. 3D) in rats with post-MI heart failure.
Plasma levels of total and high molecular weight adiponectin
in the rat model of post-myocardial infarction heart failure
Total plasma adiponectin levels were significantly lower in
rats with post-MI heart failure compared with the sham-operated
animals (Fig. 5A). However, plasma concentrations of HMW
adiponectin were not significantly different between these two
groups (Fig. 5B). There was no significant difference in HMW
to total adiponectin ratio between rats with post-MI heart failure
(0.069 ± 0.017) and sham-operated group (0.052 ± 0.031).
A positive correlation was found between plasma
adiponectin concentrations and LVSa (r = 0.731, P < 0.04) (Fig.
3E) in rats with MI-induced heart failure.
DISCUSSION
The present study was designed to examine the effect of
post-MI heart failure on total and HMW adiponectin
concentrations in the myocardium, adipose tissue in different
anatomic locations and plasma. We decided to use the rat model
of heart failure two months after MI because this particular stage
seems to be appropriate model of chronic heart failure that
mimics typical systolic chronic heart failure in humans. We
demonstrated that total adiponectin level was increased in the
LV tissue, while it was decreased in the plasma and cardiac
adipose tissue in rats with MI-induced heart failure.
Local production of adiponectin by cardiomyocytes may
permit modulation of cardiac function and metabolism (13).
Recent research has been shown that adiponectin has direct anti-
inflammatory and anti-oxidant effects, which play a role in its
cardioprotective action. Shibata and coworkers (9) observed
higher adiponectin levels in damaged cardiomyocytes following
ischemia/reperfusion injury, 24 hours after induction of MI. In
contrast, a decrease in adiponectin level in the rat myocardium
was observed two weeks after acute MI (14).
In the present study we observed for the first time a significant
increase of adiponectin in the LV tissue but not in the RV, in post-
MI heart failure, which might indicate that this protein contributes
to long-term cardioprotection in the LV hypertrophy at the time-
point of eight week after induction of MI. In the early phase, 24
hours after MI, it seems that the protective action of adiponectin is
mediated by two mechanisms: the stimulation of AMP-activated
protein kinase (AMPK) and cyclooxygenase-2 (COX-2) (15).
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Fig. 4. Total adiponectin concentrations in adipose tissue
homogenates in rats with post-myocardial infarction heart
failure (MI; n = 8) and sham-operated rats (n = 9), 8 weeks after
surgery. Results are median and interquartile range (min/max). 
* P < 0.05 by the Mann-Whitney U test.
A 
B 
o
a
W
a
d
y
t
o
o
a
e
i
d
n
u
 
 
Fig. 5. Total (A) and high molecular weight (B) adiponectin
concentrations in plasma in rats with post-myocardial infarction
heart failure (MI; n = 8) and sham-operated rats (n = 9), 8 weeks
after surgery. Results are median and interquartile range
(min/max). * P < 0.05 by the Mann-Whitney U test.
Adiponectin has been shown to improve glucose metabolism
and insulin resistance via the AMPK signaling pathway (16). In
contrast, insulin inhibits cardiac AMPK activity (17). AMPK is
a key regulator of energy metabolism in the heart and its
deficiency has been reported to be associated with depressed
cardiac function in mice (18). Recently, it was suggested that
heart failure may promote metabolic changes in cardiomyocytes
such as insulin resistance (19). Thus, an increase of adiponectin
concentration in the LV observed in our study may be an
adaptive response to left ventricular insulin resistance in the
post-MI heart failure.
Adiponectin production by myocardium is markedly lower
than that of white adipose tissue (WAT) origin. In addition, the
amount of adiponectin locally synthesized by cardiomyocytes is
too small to contribute significantly to the plasma concentrations
of adiponectin (20). It has been shown that adiponectin is
associated with many pathological processes and its synthesis is
regulated in different way depending on the fat depot location of
this protein (21). Therefore, in the present study we analyzed
how different WAT sites respond to post-MI heart failure. We
found that post-MI heart failure resulted in a significant decrease
in adiponectin levels only in cardiac adipose tissue, which may
interact locally with the myocardium. Resent research revealed
that these fat tissues expand, become hypoxic and dysfunctional
in a course of CVD (22). There are changes in adipocyte size and
reduction of the production of protective proteins including
adiponectin in favor of detrimental adipocytokines such as
leptin, resistin or IL-6. Likewise, recent research revealed that a
lower adiponectin concentration in epicardial fat was associated
with increased levels of inflammatory molecules in patients with
CAD (23). It seems highly possible that these data could explain
our findings of adiponectin decrease in cardiac adipose tissue.
Fat tissue around the heart may serve as a supportive and
mechanical factor and, additionally, it may be a vasocrine and
paracrine source of cytokines and adipokines (24). The
adiponectin receptor T-cadherin presence on cardiomyocyte
surfaces is necessary for binding adiponectin and activating its
cardioprotective actions, probably through AMPK signaling. In
a clinical study, adiponectin and T-cadherin were detected at the
periphery of damaged cardiomyocytes in patients with MI (25).
The absence of T-cadherin was found to dramatically increase
plasma adiponectin levels (26). There have been reports of
reduced total plasma adiponectin levels immediately after acute
MI (9, 27), as well as 14 days following MI in animal models
(14). Based on our data indicating that plasma adiponectin
concentrations were 25% lower in rats with post-MI heart failure
than in control rats, we speculate that the plasma adiponectin
level might be reduced by binding to T-cadherin. Another
possible explanation for the finding of plasma adiponectin levels
decline after cardiac injury is that this protein may accumulate in
damaged regions of the heart.
Using a mouse model of myocardial ischemia/reperfusion
injury, Tao and colleagues (28) observed that adiponectin-
deficient mice showed increased myocardial infarct size and
apoptosis. These authors also suggested that adiponectin exerts
cardioprotective effects by inhibiting oxidative stress (28). In
this model, injection of recombinant adiponectin protein caused
a reduction in cardiac infarct size and decreased TNF-α
production as well as improved LV function (15, 28).
Furthermore, recent evidence suggested that adiponectin may
play a protective role by reducing the infarct size through an
improvement of ischemia-reperfusion injury in the myocardial
ischemia preconditioning rat model (29). A recent study
demonstrated that swimming exercise improved the ventricular
function in rat (30). According to the author, one possible
explanation for this effect could be increase cardiac adiponectin
mRNA level (30).
Previous study indicated that pro-BNP increased, similar to
plasma adiponectin level, depending on the severity of heart
failure (31). The increased production of natriuretic peptides,
especially BNP, by cardiomyocytes was established as a
marker of heart failure in animal models and in clinical
practice (32-34). We detected elevations of ANP (33.2-fold)
and BNP (2.7-fold) mRNA levels and increased LVEDP in the
LV that supported the diagnosis of advanced heart failure in the
rat model of MI-induced heart failure. In accordance with the
present results, previous reports found that LV ANP and BNP
gene expression were significantly increased in the rat model
of MI or heart failure compared with sham-operated controls
(35-37). Increased cardiac expression of the genes encoding
ANP and BNP has been associated with myocardial
dysfunction (38) and considered a potential marker of
hypertrophic processes in a variety of in vitro (39), animal (40)
and clinical (41) models.
The report of von Eynatten et al. (42) suggested that HMW
adiponectin, the most active form of this protein, would be a
much more effective and sensitive biomarker than total
adiponectin for CAD extent. However, this association was not
identified in a subsequent study (43). Moreover, it has been
demonstrated that plasma HMW adiponectin levels decreased 24
hours after myocardial ischemia-reperfusion injury in mice (9).
However, our results indicated that plasma HMW adiponectin
levels did not change in rats with post-MI heart failure compared
with the controls. To the best of our knowledge, no other study
has examined the HMW adiponectin isoform secretion by
different adipose tissue depots and myocardial tissue in the rat
model of post-MI heart failure. As we did not observe any
differences, we speculate that the decrease of HMW adiponectin
levels may be related to early phase of MI rather than post-MI
heart failure.
There is a need to investigate new therapeutic tools for the
treatment of heart disease. One of the most promising and
realistic methods of treating MI is stem cell therapy (44).
Another strategy for treatment of cardiovascular disease is
consider the potential therapeutic benefits of cardioprotective
molecules like adiponectin. Although supplementation with
exogenous adiponectin is effective in alleviating CVD in
animals, it is still difficult to use adiponectin as a therapeutic
agent in humans. This is due to the following facts: 1) high
circulating levels of adiponectin are required for its beneficial
effects; 2) the extensive post-translational modifications are
needed for adiponectin activity; and 3) adiponectin has relatively
short half-life. We have shown that adiponectin levels were
increased in LV tissue of post-MI failure hearts in the rat model.
This effect might be caused by local production of adiponectin
by cardiomyocytes and/or transport from the plasma and/or from
cardiac adipose tissue. Our present experiments, however, did
not examine use of potential cardioprotective drugs in rat model
of MI-induced heart failure.
Further research is required to determine an alternative
therapeutic approaches focused on regulation of adiponectin
synthesis, as well as on inter-cell transport of adiponectin
between the heart, cardiac adipose tissue and plasma. In
addition, factors enhancing the sensitivity of the cardiomyocytes
should be intensively studied. Understanding the mechanisms
described above could be useful for treating LV dysfunction
following MI.
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